Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK4 | O00444 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 9/20 | 0.54 |
| ▸ | ROCK2 | O75116 | 9/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.51 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.51 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.51 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.51 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.49 |
| ▸ | SYK | P43405 | 1/20 | 0.49 |
| ▸ | BTK | Q06187 | 1/20 | 0.49 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.48 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.48 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.48 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.48 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18399012 | 0.89 | SYK (0.59) | PLK4PIK3CASYKBTKPDGFRB | |
| SCHEMBL29728069 | 0.89 | SYK (0.59) | PLK4PIK3CASYKBTKPDGFRB | |
| SCHEMBL15515501 | 0.85 | CYP3A4 (0.58) | CYP3A4ROCK2 | |
| SCHEMBL24172739 | 0.85 | CYP3A4 (0.58) | CYP3A4ROCK2CYP2D6SLC6A2SLC6A4 | |
| SCHEMBL2798618 | 0.83 | CDC7 (0.59) | CYP3A4ROCK2CYP2D6SLC6A2SLC6A4 | |
| Hydrochloric Acid SCHEMBL22412381 | 0.81 | CDC7 (0.58) | CYP3A4ROCK2CYP2D6SLC6A2SLC6A4 | |
| SCHEMBL30544684 | 0.80 | PIK3CD (0.53) | PIK3CASYKBTKPDGFRBPDE3B | |
| SCHEMBL1310062 | 0.79 | ROCK2 (0.51) | PLK4ROCK2PIK3CASYKBTK | |
| SCHEMBL5823182 | 0.79 | CYP3A4 (0.55) | CYP3A4ROCK2CYP2D6SLC6A2SLC6A4 | |
| SCHEMBL1311233 | 0.79 | GRIA1 (0.52) | ROCK2PIK3CAMAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7199147-B2 | Rho kinase inhibitors | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2007-04-03 | — | — | US | disclosed |
| US-20040138286-A1 | Rho kinase inhibitors | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2004-07-15 | — | — | US | disclosed |
| EP-1403255-A1 | Rho KINASE INHIBITORS | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2004-03-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040138286-A1 | Rho kinase inhibitors | ROCK1, ROCK2, ARHGDIA | PLK4 1774/4885CYP3A4 3113/4885ROCK2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.